FDA proposes to withdraw approval of TAVNEOS over disputed trial data
AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.
The FDA is moving to withdraw approval of TAVNEOS, a drug for severe ANCA-associated vasculitis, after concluding that key trial results may have been manipulated and that the approval file included material false statements. The agency says the pivotal study was readjusted after the database was unblinded in a way that changed the result from not significant to significant, and it is giving the sponsor a chance to request a hearing by June 1, 2026. For ChemoCentryx and current owner Amgen, the immediate issue is regulatory defense: they must decide whether to fight the proposal and submit supporting data by June 29, 2026. For hospitals, clinicians, payers, and patients using TAVNEOS, the notice does not remove the drug today, but it signals a serious risk to its U.S. approval and highlights safety concerns already seen with liver injury.
AI-generated summary. May contain errors. Refer to official sources for legal decisions.
Key Changes
- FDA proposes to withdraw TAVNEOS NDA 214487
- Agency says pivotal trial data were manipulated after database unblinding
- ChemoCentryx may request a hearing by June 1, 2026 and submit supporting data by June 29, 2026
Obligations
What this law requires
ChemoCentryx (the applicant for NDA 214487) may submit a written request for a hearing on FDA's proposal to withdraw approval of TAVNEOS.
ChemoCentryx (the applicant) may request a hearing on FDA’s proposal to withdraw approval of NDA 214487 for TAVNEOS, and if it does so it must submit the hearing request to FDA by the stated deadline.
If the applicant requests a hearing, it must submit all data, information, and analyses supporting the hearing request.
ChemoCentryx must submit all data, information, and analyses supporting its hearing request by the stated deadline if it seeks to contest FDA’s proposal.
Other interested parties may submit comments to FDA on the proposal, and those comments must be filed by the stated deadline if they are to be considered timely.